Geode Capital Management LLC Has $47.38 Million Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Geode Capital Management LLC lifted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,008,214 shares of the company’s stock after purchasing an additional 35,196 shares during the period. Geode Capital Management LLC owned 1.18% of CRISPR Therapeutics worth $47,383,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Capital Advisors Inc. OK lifted its position in CRISPR Therapeutics by 8.1% in the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock worth $14,122,000 after purchasing an additional 22,583 shares during the period. Granite Bay Wealth Management LLC acquired a new stake in CRISPR Therapeutics during the 2nd quarter valued at $2,375,000. State Street Corp lifted its position in CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after buying an additional 599,304 shares in the last quarter. International Assets Investment Management LLC bought a new position in CRISPR Therapeutics in the 3rd quarter valued at $1,825,000. Finally, FMR LLC grew its position in shares of CRISPR Therapeutics by 1.0% during the 3rd quarter. FMR LLC now owns 2,376,166 shares of the company’s stock worth $111,632,000 after buying an additional 23,075 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the transaction, the general counsel now directly owns 62,597 shares of the company’s stock, valued at $2,896,989.16. The trade was a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the sale, the chief executive officer now owns 226,540 shares of the company’s stock, valued at approximately $10,484,271.20. This trade represents a 1.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,382 shares of company stock worth $2,744,179 over the last ninety days. 4.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research note on Friday. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research report on Wednesday, December 11th. Barclays decreased their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. Chardan Capital restated a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $77.93.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $40.48 on Tuesday. The stock has a market capitalization of $3.46 billion, a P/E ratio of -14.30 and a beta of 1.62. CRISPR Therapeutics AG has a one year low of $39.41 and a one year high of $91.10. The firm’s 50 day simple moving average is $48.30 and its two-hundred day simple moving average is $50.52.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. The firm had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same quarter in the prior year, the firm posted ($1.41) earnings per share. As a group, equities analysts expect that CRISPR Therapeutics AG will post -5.13 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.